Who are Mirabegron tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): daytime dosing of mirabegron, nighttime dosing of mirabegron, amibegron (SR58611A), Placebo to Mirabegron.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mirabegron-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Mirabegron tablet — Competitive Intelligence Brief

Mirabegron tablet (Mirabegron tablet) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-3 adrenergic receptor agonist. Area: Urology.

marketed Beta-3 adrenergic receptor agonist Beta-3 adrenergic receptor (ADRB3) Urology Small molecule Live · refreshed every 30 min

Target snapshot

Mirabegron tablet (Mirabegron tablet) — Astellas Pharma Inc. Mirabegron is a beta-3 adrenergic receptor agonist that relaxes the detrusor muscle in the bladder to increase urine storage capacity.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Mirabegron tablet TARGET	Mirabegron tablet	Astellas Pharma Inc	marketed	Beta-3 adrenergic receptor agonist	Beta-3 adrenergic receptor (ADRB3)
daytime dosing of mirabegron	daytime dosing of mirabegron	Far Eastern Memorial Hospital	marketed	Beta-3 adrenergic receptor agonist	Beta-3 adrenergic receptor (ADRB3)
nighttime dosing of mirabegron	nighttime dosing of mirabegron	Far Eastern Memorial Hospital	marketed	Beta-3 adrenergic receptor agonist	Beta-3 adrenergic receptor (ADRB3)
amibegron (SR58611A)	amibegron (SR58611A)	Sanofi	phase 3	beta-3 adrenergic receptor agonist	beta-3 adrenergic receptor
Placebo to Mirabegron	Placebo to Mirabegron	Astellas Pharma Inc	phase 3	Beta-3 adrenergic receptor agonist	Beta-3 adrenergic receptor (ADRB3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-3 adrenergic receptor agonist class)

Astellas Pharma Inc · 2 drugs in this class
Far Eastern Memorial Hospital · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mirabegron tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/mirabegron-tablet. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab